← Back to Clinical Trials
Recruiting NCT07350499

NCT07350499 Aspiration Thrombectomy Using the Symphony or Prodigy System

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07350499
Status Recruiting
Phase
Sponsor Imperative Care, Inc.
Condition Arterial Thromboembolism
Study Type OBSERVATIONAL
Enrollment 750 participants
Start Date 2026-02-13
Primary Completion 2030-03

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Prodigy Thrombectomy SystemSymphony Thrombectomy SystemSymphony Thrombectomy System

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 750 participants in total. It began in 2026-02-13 with a primary completion date of 2030-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The study is designed to evaluate the short-term and long-term clinical performance and safety of the Symphony and Prodigy thrombectomy systems used in endovascular procedures across the peripheral or pulmonary vasculature.

Eligibility Criteria

Inclusion Criteria: 1. Subject is ≥ 18 years of age 2. Subject is willing and able to comply with the follow-up schedule specified in this protocol 3. Subject is willing and able to provide written informed consent prior to any study-related data collection 4. Subject has a planned procedure, involving the use of Imperative Care vascular devices within their intended use Exclusion Criteria: 1. Subjects with any contraindications per the applicable Instructions for Use 2. Subject with life expectancy of less than 1 year 3. In the opinion of the Investigator, the patient is not a suitable candidate for intervention with Imperative Care devices 4. Subject who may be unable to complete study follow-up 5. Peripheral Venous Cohort ONLY: Presence of thrombus extending more than 2 cm into the IVC on imaging

Contact & Investigator

Central Contact

Sylvie Akiel-Fu, MPH

✉ safu@imperativecare.com

📞 917-375-4735

Principal Investigator

Steven Abramowitz, MD

PRINCIPAL INVESTIGATOR

Medstar Health Research Institute

Frequently Asked Questions

Who can join the NCT07350499 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Arterial Thromboembolism. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07350499 currently recruiting?

Yes, NCT07350499 is actively recruiting participants. Contact the research team at safu@imperativecare.com for enrollment information.

Where is the NCT07350499 trial being conducted?

This trial is being conducted at Huntsville, United States, Tampa, United States, Munster, United States, Cincinnati, United States.

Who is sponsoring the NCT07350499 clinical trial?

NCT07350499 is sponsored by Imperative Care, Inc.. The principal investigator is Steven Abramowitz, MD at Medstar Health Research Institute. The trial plans to enroll 750 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology